Procainamide - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:55:29Z

Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T17:24:21Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T16:42:22Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

← Older revision		Revision as of 16:42, 20 March 2026
Line 65:		Line 65:

	==Comments==		==Comments==


			==Indications by Condition==
			''The following table is automatically generated from disease/condition pages across WikEM.''

			{{#ask:[[Has DrugName::Procainamide]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|link=subject
			\|sort=Has Indication
			\|limit=50
			}}

	==See Also==		==See Also==

2019-11-28T03:40:06Z

Arrythmia

← Older revision		Revision as of 03:40, 28 November 2019
Line 7:		Line 7:
	===[[Arrythmia]]===		===[[Arrythmia]]===
	''Drug of Choice for stable [[wide complex tachycardia]] (Class IIa recommendation)		''Drug of Choice for stable [[wide complex tachycardia]] (Class IIa recommendation)
	*17 mg/kg ~~at a rate of 20 - 50 mg/min; intravenously over 25 - 30 minutes~~		*100 mg IV x 2 min q5min as needed to max dose 17 mg/kg
	*Give until:		*Give until:
	**Arrhythmia is suppressed		**Arrhythmia is suppressed
	**Patient develops hypotension		**Patient develops hypotension
	**QRS segment prolongs by >50% of baseline		**QRS segment prolongs by >50% of baseline
	**Total of 17 mg/kg is given~~; max 1 gram~~		**Total of 17 mg/kg given
	*If effective, start continuous infusion at 1-4 mg/min		*If effective, start continuous infusion at 1-4 mg/min
	**Continuous infusion has fewer adverse effects than bolus		**Continuous infusion has fewer adverse effects than bolus

2019-09-23T21:58:13Z

References

2018-03-14T11:47:49Z

Special Populations

← Older revision		Revision as of 11:47, 14 March 2018
Line 26:		Line 26:
	*[[Lactation risk categories\|Lactation risk]]: Procainamide and its metabolite are found in breast milk. Due to the potential for adverse events in the nursing infant, breast-feeding is not recommended by the manufacturer.		*[[Lactation risk categories\|Lactation risk]]: Procainamide and its metabolite are found in breast milk. Due to the potential for adverse events in the nursing infant, breast-feeding is not recommended by the manufacturer.
	*Renal Dosing		*Renal Dosing
	**Adult		**Adult: Drip rate is 1-2 mg/min for renal/cardiac failure
	**Pediatric		**Pediatric
	*Hepatic Dosing		*Hepatic Dosing

2018-03-14T11:12:19Z

Arrythmia

← Older revision		Revision as of 11:12, 14 March 2018
Line 6:		Line 6:
	==Adult Dosing==		==Adult Dosing==
	===[[Arrythmia]]===		===[[Arrythmia]]===
	''Drug of Choice for stable [[wide complex ~~Tachycardia~~]] (Class IIa recommendation)		''Drug of Choice for stable [[wide complex tachycardia]] (Class IIa recommendation)
	*17 mg/kg at a rate of 20 - 50 mg/min; intravenously over 25 - 30 minutes		*17 mg/kg at a rate of 20 - 50 mg/min; intravenously over 25 - 30 minutes
	*Give until:		*Give until:

2018-03-14T11:12:07Z

Arrythmia

← Older revision		Revision as of 11:12, 14 March 2018
Line 6:		Line 6:
	==Adult Dosing==		==Adult Dosing==
	===[[Arrythmia]]===		===[[Arrythmia]]===
	*Considered Drug of Choice for stable ~~Wide-Complex~~ [[Tachycardia]] Class IIa ~~reccomendation~~		''Drug of Choice for stable [[wide complex Tachycardia]] (Class IIa recommendation)
	*17 mg/kg at a rate of 20 - 50 mg/min; intravenously over 25 - 30 minutes		*17 mg/kg at a rate of 20 - 50 mg/min; intravenously over 25 - 30 minutes
	*Give until:		*Give until:
	**~~arrhythmia~~ is suppressed		**Arrhythmia is suppressed
	**~~patient~~ develops hypotension		**Patient develops hypotension
	**QRS segment prolongs by >50% of baseline		**QRS segment prolongs by >50% of baseline
	**~~total~~ of 17 mg/kg is given; max 1 gram		**Total of 17 mg/kg is given; max 1 gram
	*If effective, start continuous infusion at 1-4 mg/min		*If effective, start continuous infusion at 1-4 mg/min
	**Continuous infusion has fewer adverse effects than bolus		**Continuous infusion has fewer adverse effects than bolus

2017-03-19T21:47:26Z

Arrythmia

← Older revision		Revision as of 21:47, 19 March 2017
Line 7:		Line 7:
	===[[Arrythmia]]===		===[[Arrythmia]]===
	*Considered Drug of Choice for stable Wide-Complex [[Tachycardia]] Class IIa reccomendation		*Considered Drug of Choice for stable Wide-Complex [[Tachycardia]] Class IIa reccomendation
	*~~17mg~~/kg at a rate of 20 - ~~50mg~~/min; intravenously over 25 - 30 minutes		*17 mg/kg at a rate of 20 - 50 mg/min; intravenously over 25 - 30 minutes
	*Give until:		*Give until:
	**arrhythmia is suppressed		**arrhythmia is suppressed
	**patient develops hypotension		**patient develops hypotension
	**QRS segment prolongs by >50% of baseline		**QRS segment prolongs by >50% of baseline
	**total of ~~17mg~~/kg is given; max 1 gram		**total of 17 mg/kg is given; max 1 gram
	*If effective, start continuous infusion at 1-~~4mg~~/min		*If effective, start continuous infusion at 1-4 mg/min
	**Continuous infusion has fewer adverse effects than bolus		**Continuous infusion has fewer adverse effects than bolus

2016-07-21T11:01:21Z

Text replacement - "5 mg" to "5mg"

← Older revision		Revision as of 11:01, 21 July 2016
Line 19:		Line 19:
	===[[Arrythmia]]===		===[[Arrythmia]]===
	*Stable wide-complex [[tachycardia]] or [[SVT]]		*Stable wide-complex [[tachycardia]] or [[SVT]]
	*~~15 mg~~/kg infused over 30-60 minutes		*15mg/kg infused over 30-60 minutes
	**Stop infusion if hypotension occurs or QRS complex widens by >50% of baseline		**Stop infusion if hypotension occurs or QRS complex widens by >50% of baseline